// App-Quantinova.ai

LB1904 : A COMPARISON OF CLINICAL OUTCOMES FROM ZUMA-5 (AXICABTAGENE CILOLEUCEL) AND THE INTERNATIONAL SCHOLAR-5 EXTERNAL CONTROL COHORT IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (R/R FL)

Researchers

Presenter

  • Paola Ghione

Principal Investigators

  • Anik Patel

  • Sabela Bobillo

  • Kevin Deighton

  • Caron Jacobson

  • Myrna Nahas

  • Anthony Hatswell

  • Steve Kanters

  • Julia Thornton Snider

  • Sattva Neelapu

  • Herv Ghesquieres

  • Lia Palomba

  • John Radford

  • John Gribben

Medical Centers

  • Centre Hospitalo-Universitaire Lyon Sud, Lyon, France

  • Vall d'Hebron Institute of Oncology, Barcelona, Spain

  • Kite, a Gilead company ,Santa Monica,United States

  • The Christie NHS Foundation Trust and University of Manchester, Manchester, United Kingdom

  • Department of Statistical Sciences, University College London, London, United Kingdom

  • University of Texas MD Anderson Cancer Center, Houston, Texas, United States

  • Kite, A Gilead Company,Santa Monica,United Kingdom

  • Cancer Research UK,Barts Centre,London,United Kingdom

  • Medicine,Roswell Park Comprehensive Cancer Center,Buffalo,United States

  • Dana-Farber Cancer Institute, Boston, MA, United States

  • Memorial Sloan-Kettering Cancer Center, New York, NY, United States

  • Delta Hat,Nottingham,United Kingdom

  • RainCity Analytics,Vancouver,Canada

Locations

  • France

  • Spain

  • United States

  • United Kingdom

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Follicular lymphoma

Biomarkers

  • N/A

Drug/Treatment

  • Axicabtagene ciloleucel

  • Idelalisib

  • Techniclone TNT

Outcome

  • N/A

Study Design

  • Multinational

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved